S11.2 Efficacy and safety of deucravacitinib, a selective TYK2 inhibitor, in patients with active systemic lupus erythematosus: results from a phase 2, randomized, double-blind, placebo-controlled study

• S Banerjee,
• S Singhal,
• V Shah,
• R Van Vollenhoven,
• M Pike,
• E Morand,
• I Catlett,
• VP Werth,
• JT Merrill,
• N Delev,
• C Hobar,
• B Sharkey,
• T Wegman

Affiliations

S Banerjee

Paediatric Department, Bedford Hospital NHS Trust, Bedford, UK

S Singhal

1Child Development, KK Women’s and Children’s Hospital, Singapore, Singapore

V Shah

1Radiology and Biomedical Imaging, UCSF, San Francisco, CA

R Van Vollenhoven

5 Karolinska University Hospital, Stockholm, Sweden

M Pike

11Department of Paediatric Neurology, Oxford University Hospitals NHS Trust, Oxford, UK

E Morand

4Monash University, Melbourne, Australia

I Catlett

Vertex Pharmaceuticals Incorporated, Cambridge, Massachusetts, USA

VP Werth

3Corporal Michael J. Crescenz Veterans Affairs, Medical Centre Philadelphia PA, Philadelphia, USA

JT Merrill

1Oklahoma Medical Research Foundation, Clinical Pharmacology, Oklahoma, USA

N Delev

1Bristol Myers Squibb ~ Lawrenceville, NJ ~ USA

C Hobar

6Bristol Myers Squibb ~ Princeton ~ USA

B Sharkey

6Bristol Myers Squibb ~ Princeton ~ USA

T Wegman

6Bristol Myers Squibb ~ Princeton ~ USA